Broyhill Asset Management, an investment advisor, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. 2025 witnessed extreme market concentration and a strong focus on artificial intelligence, leaving many sectors behind. The Portfolio, which has been significantly reshaped, now trades at a substantial discount relative to the broader market. The firm strongly believes it will benefit as market fundamentals improve. For the year, the portfolio declined by 1.4%, un ...

Take a look at today's bull of the day. A Zach's ranked number one, strong buy. And today's bear of the day, a Zach's rank number five, strong cell.Visit zachs. com/bull to get seven stocks set to outperform the market over the next 30 days. ...

Group 1 - Avantor Inc. (NYSE:AVTR) is considered one of the most undervalued mid-cap stocks currently available for investment [1] - Bank of America analyst Michael Ryskin lowered the price target for Avantor to $11 from $13 while maintaining a Neutral rating due to a weak FY 2026 guidance [1][2] - Citi also reduced its price target for Avantor to $11 from $13, citing Q4 2025 results and FY 2026 guidance that fell below expectations, particularly highlighting the low earnings-per-share guidance of $0.15 to $0.16 [3] Group 2 - Avantor provides essential products and services across various sectors including biopharma, healthcare, education, government, advanced technologies, and applied materials globally [4]

Core Insights - Avantor is undergoing a "fundamental shift" in its operational structure, reorganizing into two new business units: a "product-agnostic channel" and a "channel-agnostic product business" [2] - The company has launched "Project Revival" aimed at sharpening strategic focus and improving execution, built around five key pillars [3][7] - Management has committed to the VWR brand for the channel business and plans significant investments in digital capabilities, including a $10 million to $15 million upgrade in 2026 [1][4] Financial Performance - For Q4 2025, Avantor reported revenue of $1.66 billion, a 4% decline year-over-year on an organic basis, with adjusted EPS of $0.22 and free cash flow of $117 million [5][13] - Full-year 2025 revenue was $6.552 billion, down 3% organically, with adjusted EBITDA of $1.069 billion and free cash flow of $496 million [14] - For 2026, the company anticipates organic revenue growth of -2.5% to -0.5%, with adjusted EPS guidance of $0.77 to $0.83 and free cash flow of $500 million to $550 million [6][22] Segment Performance - The new reporting segments will include VWR Distribution and Services, which accounted for approximately $4.4 billion of revenue in 2025, and Bioscience and Medtech Products, which represented about $1.8 billion [21] - In Q4, Laboratory Solutions revenue was $1.116 billion and Bioscience Production revenue was $548 million, both down 4% organically [16] - The company expects VWR to "somewhat outpace" growth in the Bioscience and Medtech Products segment due to challenging comparisons in the latter [19] Operational Strategy - Avantor has identified $20 million in investments to enhance customer service capabilities and established a project management office to coordinate efforts under Project Revival [8] - The company is focusing on organic revenue growth as a key metric for tracking the progress of its revival strategy [24] - Management noted that the biopharma end market remains healthy, with expected growth in biologics demand in 2026 and beyond [11]

Core Viewpoint - Cencora reported quarterly earnings of $4.08 per share, exceeding the Zacks Consensus Estimate of $4.07 per share, and showing an increase from $3.73 per share a year ago, indicating a positive earnings surprise of +0.35% [1] Financial Performance - Cencora's revenues for the quarter ended December 2025 were $85.93 billion, slightly missing the Zacks Consensus Estimate by 0.04%, but up from $81.49 billion year-over-year [2] - The company has surpassed consensus EPS estimates in all four of the last quarters and has topped revenue estimates three times during the same period [2] Stock Performance - Cencora shares have increased approximately 7.1% since the beginning of the year, outperforming the S&P 500, which gained 1.1% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $4.86 for the coming quarter and $17.62 for the current fiscal year, alongside projected revenues of $79.49 billion and $339.88 billion respectively [7] - The Zacks Rank for Cencora is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical Services industry, to which Cencora belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges ahead [8]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Duoning Biotechnology Co., Ltd. 上海多寧生物科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資料予香港公眾人士。 本 申 請 版 本 為 草 擬 本，其 內 所 載 資 料 並 不 完 整，亦 可 能 會 作 出 重 大 變 動。閣 下 閱 覽 本 文 件，即 代 表 閣下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或承銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據送呈香港公司註冊處處長登 記的本公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (i) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據 ...

Group 1 - Avantor, Inc. (NYSE:AVTR) has been downgraded by Jefferies from Hold to Underperform, with a price target reduced from $12 to $9, citing ongoing margin headwinds and market share losses as significant concerns [1] - BofA also downgraded Avantor from Buy to Neutral on December 15, lowering the price target from $14 to $13, while indicating that 2026 is expected to be the third consecutive year of market normalization, with Life Science Tools headwinds diminishing [2] - Avantor operates in the life sciences tools sector, providing essential services and products to industries such as biopharma, healthcare, and advanced technologies [2] Group 2 - Analysts express caution regarding the potential for Avantor, suggesting that the biggest upside risk in the Tools/CRO markets would be a resurgence in spending by Biopharma [2] - The company is viewed as undervalued, but analysts believe that certain AI stocks may present greater upside potential with less downside risk [3]

Group 1 - The unusual options activity for Avantor (AVTR) indicates a significant interest in the $9 put option expiring on January 16, 2026, with a Vol/OI ratio of 437.51, suggesting heightened market activity and sentiment [1][2] - The volume of the $9 put option reached 73,647, which is more than 11 times the 30-day average, indicating a strong market reaction possibly linked to increased calls for a class action lawsuit against the company [2] - The trading activity suggests a divide in investor sentiment, with some believing the stock will not fall below $9, while others seek downside protection as the stock may decline further [3] Group 2 - The breakdown of the put trades shows that four trades accounted for 99.6% of the volume, with prices ranging from $0.05 to $0.10 per contract, indicating significant investor engagement [5] - Selling the $9 put contracts for $0.05 could yield an annualized return of 6.8%, presenting a potential income strategy for investors [7] - If the stock falls to $8.95, the breakeven point, investors may face assignment and be required to purchase shares at $9, which poses a risk if the stock continues to decline [8] Group 3 - The stock has never traded below $5 since its IPO in May 2019, with a historical low of $6.66 in March 2020, suggesting a strong support level above this threshold [9]

Group 1 - U.S. stock futures are higher, with Dow futures gaining approximately 0.2% [1] - Lennar Corp reported fourth-quarter revenue of $9.37 billion, exceeding analyst estimates of $9.02 billion [1] - Lennar's adjusted earnings for the quarter were $2.03 per share, falling short of estimates of $2.21 per share [1] Group 2 - Lennar shares fell 3.8% to $113.12 in pre-market trading [2] - AlphaVest Acquisition Corp experienced a significant drop of 19.8% to $8.26 in pre-market trading after a previous gain of 31% [3] - Kyverna Therapeutics Inc declined 19.2% to $8.27 in pre-market trading following a recent announcement of a $100 million offering [3] - Bally's Corporation shares decreased by 11.2% to $15.17 in pre-market trading [3] - Worthington Enterprises, Inc. saw a decline of 8.2% to $51.65 in pre-market trading after reporting mixed second-quarter financial results and announcing an acquisition of LSI Group [3] - Bread Financial Holdings Inc dipped 6.3% to $71.00 in pre-market trading [3] - Avantor, Inc. fell 3.6% to $10.80 in pre-market trading [3] - NovaBay Pharmaceuticals, Inc. decreased by 3.5% to $3.05 in pre-market trading after a previous jump of over 16% [3] - Cementos Pacasmayo S.A.A. declined 3.2% to $10.30 in pre-market trading after a significant increase of 52% on Tuesday due to Holcim's agreement to purchase a majority stake [3] - Sweetgreen, Inc. fell 3.1% to $6.70 in pre-market trading [3]

Group 1 - U.S. stock futures are higher, with Dow futures gaining approximately 0.2% [1] - Lennar Corp reported fourth-quarter revenue of $9.37 billion, exceeding analyst estimates of $9.02 billion [1] - Lennar's adjusted earnings for the quarter were $2.03 per share, falling short of estimates of $2.21 per share [1] Group 2 - Lennar shares fell 3.8% to $113.12 in pre-market trading [2] - AlphaVest Acquisition Corp experienced a significant drop of 19.8% to $8.26 in pre-market trading after a previous gain of 31% [3] - Kyverna Therapeutics Inc declined 19.2% to $8.27 in pre-market trading following a recent announcement of a $100 million offering [3] - Bally's Corporation shares decreased by 11.2% to $15.17 in pre-market trading [3] - Worthington Enterprises, Inc. saw a decline of 8.2% to $51.65 in pre-market trading after reporting mixed second-quarter financial results and announcing an acquisition of LSI Group [3] - Bread Financial Holdings Inc dipped 6.3% to $71.00 in pre-market trading [3] - Avantor, Inc. fell 3.6% to $10.80 in pre-market trading [3] - NovaBay Pharmaceuticals, Inc. decreased by 3.5% to $3.05 in pre-market trading after a previous jump of over 16% [3] - Cementos Pacasmayo S.A.A. declined 3.2% to $10.30 in pre-market trading after a significant increase of 52% on Tuesday due to Holcim's agreement to purchase a majority stake [3] - Sweetgreen, Inc. fell 3.1% to $6.70 in pre-market trading [3]